Literature DB >> 23229328

Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab?

Manreet Kaur, Stephen R Targan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23229328     DOI： 10.1038/nrgastro.2012.235

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis.

Authors:  F A Rowe; J H Walker; L C Karp; E A Vasiliauskas; S E Plevy; S R Targan
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

2.  Intensive intravenous regimen for severe attacks of ulcerative colitis.

Authors:  S C Truelove; D P Jewell
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

3.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.

Authors:  David N Moskovitz; Gert Van Assche; Benedikte Maenhout; Joris Arts; Marc Ferrante; Severine Vermeire; Paul Rutgeerts
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-22       Impact factor: 11.382

5.  Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Authors:  B E Sands; W J Tremaine; W J Sandborn; P J Rutgeerts; S B Hanauer; L Mayer; S R Targan; D K Podolsky
Journal:  Inflamm Bowel Dis       Date:  2001-05       Impact factor: 5.325

6.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

7.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Authors:  S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

8.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

9.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

10.  Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study.

Authors:  Giovanni C Actis; Maurizio Fadda; Ezio David; Anna Sapino
Journal:  BMC Gastroenterol       Date:  2007-03-27       Impact factor: 3.067
  10 in total
  1 in total

1.  Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.

Authors:  Eun Hye Kim; Duk Hwan Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.